Latest Breaking News On - Preserved ejection fraction - Page 3 : comparemela.com

CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024

BETHESDA, Md. (BUSINESS WIRE) Apr 7, 2024

United statesGrant smithCorvista health incGeorgia world congress centerCorvista healthAmerican college of cardiologyLife incAvista healthNon invasive point of care rule out testHeart failureMachine learningAmerican collegeAnnual scientific sessionCorvista systemPreserved ejection fractionCharles bridges

American College of Cardiology Sets Full Range of Education Sessions and Meetings ACC Scientific Session, ACC 24

In gearing up for its Annual Scientific Session, ACC.24, amidst the 75th anniversary of the organization, the American College of Cardiology (ACC) has planned a full range of educational programming, special events and peer networking scheduled throughout the April 6-8 event in Atlanta, GA.

Alison baileyTylerj gluckmanValentin fusterLeaders mentorship programCv team section meeting receptionCv team members meet greet breakfastGeorgia world congress centerCv team handsPharmacology programCommunity dayAmerican college of cardiologyYour fit councilPersonalized skills simulation centerReproductive health cardioCare team sessionProgram directors graduate medical educators symposium

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBrian mullenChris giordanoBaylor scott whiteDaniel burkhoffSanjiv shahJaved butlerJohn frauncesNorthwestern universityResearch for the bluhm cardiovascular instituteCompany secured global commercial rights to levosimendanLifesci advisorsOrion corporationTenax therapeutics incCardiovascular research foundation technologyNasdaq stock market

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results - Tenax Therapeutics (NASDAQ:TENX)

First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S.

United statesJohn frauncesBaylor scott whiteDaniel burkhoffChris giordanoSanjiv shahJaved butlerBrian mullenCardiovascular research foundation technologyTrademark officeLifesci advisorsOrion corporationCompany secured global commercial rights to levosimendanNorthwestern universityTenax therapeutics incColumbia university

THT 2024 Late-Breaking Clinical Science Announced

The complete list of late-breaking clinical science to be presented at THT 2024: Technology and Heart Failure Therapeutics is now available online. An internat

United statesTufts medical centerNew yorkCleveland clinicWilliamt abrahamGabriel sayerDaniel burkhoffDavidm kayeJoann lindenfeldSanjivj shahNavink kapurJerryd estepSeanp pinneyUlrichp jordeSteveno marxAdamb greenbaum